CEO's first open-market buy in this window after strong Q2 results and guidance raise is a credible bullish signal consistent with insider-literature patterns. However, the buy size is negligible relative to PFE's $152.7B market cap — treat as a conviction signal, not a liquidity event. Monitor for additional insider buys (especially C-suite) and any share buyback program announcements that could validate the signal at scale. The stock's current price of $26.87 is essentially flat to Bourla's purchase price — limited immediate catalyst.
Price Chart
Executive Summary
Pfizer Chairman & CEO Albert Bourla made an open-market purchase of $1.0M worth of shares at $26.34 on August 12, 2026 — his first open-market buy in the reported window. This purchase follows a strong Q2 earnings beat (12.9% on adjusted EPS) and a raised revenue guidance midpoint by $500M, signaling insider conviction that the stock is undervalued despite GAAP net loss from $4.3B in intangible asset impairments. At $152.7B market cap, the $1.0M buy represents ~0.001% of market cap — proportionally tiny — but as a standalone CEO conviction buy backed by solid operational results, it carries meaningful signal per insider-trading literature.
Key Financial Metrics
Key Facts
- Chairman & CEO Albert Bourla purchased 38,000 shares at $26.34 for total of $1,000,920 on August 12, 2026
- Purchase is an open-market buy (SEC code P), not a grant or exercise — CEO is deploying personal capital
- Purchase comes 8 days after Pfizer reported Q2 2026 adjusted EPS beat of 12.9% ($0.77 vs $0.68 consensus) and raised FY2026 revenue guidance midpoint by $500M to $60.5-$62.5B
- Bourla also received a 22-share grant on August 14 ($589) — de minimis, but consistent with normal administrative pattern
- Pfizer has $152.7B market cap — the $1.0M open-market purchase represents ~0.001% of market cap, proportionally tiny
- Recent insider activity (30d): 3 buys totaling $3.0M and 1 sell of $83K — net buying trend
Financial Impact
CEO open-market purchase of $1.0M at $26.34 per share, representing ~0.001% of market cap
Risk Factors
- Purchase is proportionally trivial (~0.001% of market cap) — may not reflect a material conviction view
- Pfizer reported a GAAP net loss of $0.04 per share due to $4.3B in non-cash intangible impairments — underlying earnings quality is mixed
- Historical performance on PFE reports shows 0% win rate at T+20 (n=3 settled) — past signals have underperformed
- No 10b5-1 plan exclusion available — this buy could be pre-planned, though open-market purchases are less likely to be 10b5-1 sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001225208-26-007083 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | Court Ruling | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.55 (+2.78%) |
Aug 12, 2026 7w ago | Insider Buy | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.55 (+2.78%) |
Aug 12, 2026 7w ago | Insider Cluster | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.55 (+2.78%) |
Aug 6, 2026 8w ago | Insider Cluster | $26.20 $28.81 | ▲ +9.95% | ▲ +9.35% | $27.55 (+5.13%) |
Aug 5, 2026 8w ago | Insider Cluster | $26.20 $28.81 | ▲ +9.95% | ▲ +9.35% | $27.55 (+5.13%) |
Aug 4, 2026 8w ago | 8-K | $25.41 $28.55 | ▲ +12.36% | ▲ +13.60% | $27.55 (+8.40%) |
Jul 31, 2026 9w ago | Court Ruling | $25.01 $27.96 | ▼ −11.80% | ▼ −8.81% | $27.55 (−10.14%) |
Jul 24, 2026 10w ago | Court Ruling | $24.54 $28.07 | ▲ +14.38% | ▲ +10.76% | $27.55 (+12.25%) |
Jul 6, 2026 12w ago | ANALYST-DOWNGRADE | $23.72 $25.01 | ▼ −5.44% | ▼ −6.00% | $27.55 (−16.13%) |
Jun 18, 2026 15w ago | 8-K | $25.21 $25.14 | ▼ −0.28% | ▼ −0.81% | $27.55 (+9.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access